Navigation Links
Dendreon Reports Third Quarter 2010 Financial Results
Date:11/3/2010

eptember 30, 2010 was $347.6 million, or $2.54 per share, which includes a non-cash charge associated with the revaluation of warrants of $142.6 million or $1.04 per share, compared to $187.7 million, or $1.79 per share for the nine months ended September 30, 2009, which included a non-cash charge of $122.8 million or $1.17 per share for warrant revaluation.

As of September 30, 2010, Dendreon had $392.7 million in cash, cash equivalents, and short-term and long-term investments compared to $606.4 million as of December 31, 2009.

Highlights include:

  • Since approval Dendreon has received over 1,000 prescriptions for PROVENGE.
  • Dendreon is on track to make PROVENGE more broadly available in 2011 with the expansion and anticipated licensure of its New Jersey facility in early 2011 and its facilities in Atlanta, Georgia and Orange County, California in mid-2011, for which construction is substantially complete.
  • Dendreon’s revenue guidance for full year 2010 is approximately $46-47 million and for 2011 is expected to be in the range of $350-400 million, with approximately half of that expected to be generated in Q4, based on a standard FDA review period and approval of our new manufacturing facilities.
  • PROVENGE data were presented at the Asian Congress of Urology, European Society of Medical Oncology, and the International Society for Biological Therapy of Cancer.

  • Conference Call InformationDendreon will host a conference call today at 1:30 p.m. PT, 4:30 p.m. ET. To access the live call, dial 1-866-730-5769 (domestic) or +1-857-350-1593 (international); the conference pass code is 35737817. The call will also be audio webcast and will be available from the Company's website at www.dendreon.com under the "Investor/Webcasts and Presentations" section. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call b
    '/>"/>

    SOURCE Dendreon Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Dendreon Announces Presentation of PROVENGE Data at the 25th International Society for Biological Therapy of Cancer Annual Meeting
    2. Dendreon Statement on CMS National Coverage Analysis
    3. Dendreon Announces Presentation of PROVENGE Data at the American Urological Association Annual Meeting
    4. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
    5. Dendreon Reports Fourth Quarter and 2009 Year End Financial Results
    6. Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
    7. Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
    8. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
    9. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
    10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
    11. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/1/2014)... PALO ALTO, Calif. , Aug. 1, 2014 /PRNewswire/ ... announced a partnership to expand awareness of proper nutritional ... CFChef Shares program. CFChef Shares will run from August ... CFChef program – an online resource for CF patients ... healthy diet by submitting recipes to the Chef4CF.com ...
    (Date:8/1/2014)... Minn. , Aug. 1, 2014 ... medical technologies company, announced today that it has ... held manufacturer of cardiorespiratory diagnostic products based in ... MediSoft has served the European cardiorespiratory diagnostics market ... 2013 revenues of approximately €4.7 million ($6.3 million) ...
    (Date:8/1/2014)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... study evaluating ISIS-SMN Rx in infants with spinal ... infant mortality. Isis plans to dose the first infant ... which time Isis will earn an $18 million milestone ... 3 study, ENDEAR, is the first of several planned ...
    Breaking Medicine Technology:AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 2Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 5
    ... UNION CITY, Calif., Sept. 9, 2011 Abaxis, Inc. ... analysis systems, announced today that Clint Severson, chairman and ... Annual Best Ideas Conference 2011 on Wednesday, September 14, ... held at The Omni Berkshire Place Hotel in New ...
    ... Inc. (" Valeant ") (NYSE/TSX:VRX), announced today that Valeant mailed ... ") its offer and take-over bid circular in connection with ... all of the outstanding common shares of Afexa (the " ... per Common Share. The Offer expires at 5:00p.m. ...
    Cached Medicine Technology:Abaxis, Inc. to Present at CL King's 9th Annual Best Ideas Conference 2011 2Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa 2Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa 3Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa 4
    (Date:8/1/2014)... Diego School of Medicine report that dietary capsaicin ... activation of a receptor on cells lining the intestines ... risk of colorectal tumors. , The findings are published ... Journal of Clinical Investigation . , The receptor or ... neurons, where it acts as a sentinel for heat, ...
    (Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, ... manufacturing jobs may have significantly less endurance than those who weigh ... people -- half were obese, half were of normal weight -- ... 60 percent longer. Obesity also was associated with less strength, ... older -- 50 to 65 years of age -- neither improved ...
    (Date:8/1/2014)... Ohio In a first-of-its-kind study, researchers at University ... that lap infants may be at greater risk for ... pediatric medical emergencies on flights worldwide between January 2010 ... occurred in children under the age of 2. ... to characterize the rare event of an in-flight pediatric ...
    (Date:8/1/2014)... (PRWEB) August 01, 2014 As AndroGel ... the country, Ronald E. Johnson, Jr. has been appointed ... AndroGel and other testosterone medications. Since the Fall of ... P.S.C. have worked diligently to investigate and prosecute the ... embolisms, and blood clots as a result of taking ...
    (Date:8/1/2014)... Texas (PRWEB) August 01, 2014 ... health coverage and healthcare reforms are boosting healthcare ... of medicines through discounts and increasing generic consumption ... at approximately 76.7 million in 2013, having grown ... 1.4%, from 2008. The implementation of the Health ...
    Breaking Medicine News(10 mins):Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:New research characterizes in-flight pediatric deaths 2Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4
    ... , 221.10.254.64 COLUMBIA, Mo. Due to changing ... be screened for breast cancer with mammograms, many women ... years and older get a mammogram every year, but ... other year for women older than 50. A University ...
    ... to help oncologists keep up to date with the ... been launched by the European Society for Medical Oncology ... and news organization. OncologyPRO Oncology Professional ... -- integrating regularly updated oncology news, clinical research, biomarker ...
    ... An early phase multiple myeloma trial has unexpectedly ... in cells that affect its dose level in the ... Cancer Center Arthur G. James Cancer Hospital and ... conducted the study., Lenalidomide is an anti-inflammatory drug, and ...
    ... MONDAY, Aug. 8 (HealthDay News) -- Older patients with ... verbal memory impairment, a new study finds. Verbal ... compared heart failure severity and cognitive function -- including ... for potential heart transplantation. Heart failure severity was ...
    ... features of the influenza virus,s entry point into human ... flu vaccine to protect against a broad range of ... to develop, produce, and distribute a new vaccine for ... Stephen C. Harrison, PhD, chief of the Division of ...
    ... new source for sexual problems among middle-aged and older ... men,s closest friends. Cornell University and University of ... and the social networks shared by heterosexual men and ... betweenness." In such cases, a man,s female partner has ...
    Cached Medicine News:Health News:Doctors, women should spend more time discussing mammograms 2Health News:OncologyPRO -- a revolutionary resource for oncologists 2Health News:Study urges caution with lenalidomide dosage 2Health News:Fine-tuning the flu vaccine for broader protection 2Health News:When a man's female partner becomes too buddy-buddy with his pals, his sex life may suffer 2
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: